5′-CpG Island Methylation of the FHIT Gene is Associated with Reduced Protein Expression and Higher Clinical Stage in Cervical Carcinomas

References

• Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma- associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587–597.
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol. 2002;3:748–754.
   PubMed Web of Science ®Google Scholar
• Greenspan DL, Connolly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 1997;57:4692–4698.
   PubMed Web of Science ®Google Scholar
• Helland A, Kraggerud SM, Kristensen GB, et al. Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival. Int J Cancer. 2000;88:217–222.
   PubMed Web of Science ®Google Scholar
• Chu TY, Shen CY, Chiou YS, et al. HPV-associated cervical cancers show frequent allelic loss at 3p14 but no apparent aberration of FHIT mRNA. Int J Cancer. 1998;75:199–204.
   PubMed Web of Science ®Google Scholar
• Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20:1509–1518.
   PubMed Web of Science ®Google Scholar
• Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1511–1516.
   PubMed Web of Science ®Google Scholar
• Kashiwabara K, Oyama T, Sano T, Fukuda T, Nakajima T. Correlation between methylation status of the p16=CDKN2 gene and the expression of p16 and Rb proteins in primary non- small cell lung cancers. Int J Cancer. 1998;79:215–220.
   PubMed Web of Science ®Google Scholar
• Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002;8:514–519.
   PubMed Web of Science ®Google Scholar
• Zochbauer-Muller S, Fong KM, Maitra A, et al. 50 CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 2001;61:3581–3585.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shimada Y, Harada H, et al. Methylation of the 50 CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res. 1998;58:3429–3434.
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Palamarchuk A, Huebner K, Croce CM. FHIT as tumor suppressor: mechanisms and therapeutic opportunities. Cancer Biol Ther. 2002;1:232–236.
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ. Cancer in women. Malden, MA: Blackwell Science; 1998.
   Google Scholar
• Sambrook J, Fritsch EF, T. Maniatis. Molecular Cloning: A Laboratory Manual, vol 2, ed. 2. Cold Spring Harbor,NY: Cold Spring Harbor Press; 1989.
   Google Scholar
• Liu FS, Hsieh YT, Chen JT, Ho ES, Hung MJ, Lin AJ. FHIT (fragile histidine triad) gene analysis in cervical intraepithelial neoplasia. Gynecol Oncol. 2001;82:283–290.
   PubMed Web of Science ®Google Scholar
• Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 1996;85:17–26.
   PubMed Web of Science ®Google Scholar
• Sozzi G, Andriani F, Gramegna M, Roz L. Involvement of FHIT in lung carcinogenesis prospects for future clinical gene therapy applications. Suppl Tumori. 2002;14:S62.
   Google Scholar
• Ingvarsson S. FHIT alterations in breast cancer. Semin Cancer Biol. 2001;11:361–366.
   Google Scholar
• Yang Q, Nakamura M, Nakamura Y, et al. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res. 2002;8:2890–2893.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kim CJ, Park HK, et al. Characterization of aberrant FHIT transcripts in gastric adenocarcinomas. Exp Mol Med. 2001;33:124–130.
   PubMed Web of Science ®Google Scholar
• Caselli M, Marchisio M, Gaudio M, et al. Fhit protein expression in human gastric cancer and related precancerous lesions. Oncol Rep. 2001;8:1233–1237.
   PubMed Web of Science ®Google Scholar
• Capuzzi D, Santoro E, Hauck WW, et al. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer. 2000;88:24–34.
   PubMed Web of Science ®Google Scholar
• Chaudhuri AR, Khan IA, Prasad V, Robinson AK, Luduena RF, Barnes LD. The tumor suppressor protein Fhit: a novel interaction with tubulin. J Biol Chem. 1999;274:24378–24382.
   PubMed Web of Science ®Google Scholar
• Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA. 1999;96:8489–8492.
   PubMed Web of Science ®Google Scholar
• Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 1999;59:3333–3339.
   PubMed Web of Science ®Google Scholar
• Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA. 2002;99:3615–3620.
   PubMed Web of Science ®Google Scholar
• Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2=p16=MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525–4530.
   PubMed Web of Science ®Google Scholar
• Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res. 2001;7:584–589.
   PubMed Web of Science ®Google Scholar
• Yoshino K, Enomoto T, Nakamura T, et al. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer. 1998;76:176–181.
   PubMed Web of Science ®Google Scholar
• Segawa T, Sasagawa T, Yamazaki H, Sakaike J, Ishikawa H, Inoue M. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma. Cancer. 1999;85:2001–2010.
   PubMed Web of Science ®Google Scholar